Phase III trial in patients with multiple myeloma to optimize bortezomib based induction (bortezomib, Adriamycin, dexamethasone [PAd] vs. bortezomib, cyclophosphamide, dexamethasone [VCD]) prior to high dose therapy and autologous stem cell transplantation followed by lenalidomide based consolidation and maintenance therapy.

Trial Profile

Phase III trial in patients with multiple myeloma to optimize bortezomib based induction (bortezomib, Adriamycin, dexamethasone [PAd] vs. bortezomib, cyclophosphamide, dexamethasone [VCD]) prior to high dose therapy and autologous stem cell transplantation followed by lenalidomide based consolidation and maintenance therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Lenalidomide; Melphalan
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms MM5
  • Most Recent Events

    • 12 Dec 2017 Results (n=502) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 27 Feb 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.
    • 27 Feb 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top